439239-90-4

Basic information

• Product Name: LasMiditan
• Synonyms: LasMiditan;2,4,6-trifluoro-N-(6-(1-Methylpiperidine-4-carbonyl)pyridin-2-yl)benzaMide;2,4,6-Trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]benzamide;COL 144;LY573144;LasMiditan (COL-144;Benzamide, 2,4,6-trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]-;2,4-difluoro-N-(6-(1-methylpiperidine-4-carbonyl)pyridin-2-yl)benzamide
• CAS NO: 439239-90-4
• Molecular Formula: C₁₉H₁₈F₃N₃O₂
• Molecular Weight: 377.3603296
• Product Categories: API
• Mol File: 439239-90-4.mol
• Article Data: 7

Chemical Properties

• Melting Point: 255℃
• Boiling Point: 433.3±45.0 °C(Predicted)
• Appearance: /
• Density: 1.351
• Storage Temp.: -20°C Freezer, Under inert atmosphere
• Solubility: Chloroform (Slightly), DMSO (Slightly)
• PKA: 9.91±0.70(Predicted)
• CAS DataBase Reference: LasMiditan(CAS DataBase Reference)
• NIST Chemistry Reference: LasMiditan(439239-90-4)
• EPA Substance Registry System: LasMiditan(439239-90-4)

Safety Data

• Hazardous Substances Data: 439239-90-4(Hazardous Substances Data)

Usage

Description

Lasmiditan (Item No. 28369) is an analytical reference standard categorized as an agonist of the serotonin (5-HT) receptor subtype 5-HT1F. Formulations containing lasmiditan have been used in the treatment of migraine headache. Lasmiditan has low abuse potential. Lasmiditan is regulated as a Schedule V compound in the United States. This product is intended for research and forensic applications.

Uses

Lasmiditan is used in diagnosing, treating and/or preventing periodontal disease and/or tooth loss.

Upstream product

• 103640-16-0 1-methylpiperidine-4-carboxylic acid diethylamide 
• 24252-37-7 ethyl 1-methylisonipecotate 
• 215950-19-9 1-methyl-piperidine-4-carboxylic acid methoxy-methyl-amide 
• 221087-47-4 N-(6-bromopyridin-2-yl)-2,2-dimethylpropanamide 
• 71985-80-3 1-methylpiperidine-4-carboxylic acid hydrochloride 
• 613678-14-1 (1-methyl-4-piperidyl)pyrrolidin-1-ylmethanone 
• 36052-26-3 methyl 6-aminopyridine-2-carboxylate 
• 5382-23-0 4-chloro-N-methyl-piperidine hydrochloride 
• 28314-80-9 2,4,6-trifluorobenzoic acid 
• 504-29-0 2-aminopyridine 
• 41776-24-3 1-methylpiperidine-4-carboxylic acid chloride 
• 79538-29-7 2,4,6-trifluorobenzoyl chloride 
• 19798-81-3 2-Amino-6-bromopyridine 
• 68947-43-3 1-methylpiperidine-4-carboxylic acid 

Downstream Products

• 439239-92-6 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)pyridin-2-yl]benzamide hemisuccinate 
• 439239-92-6 2,4,6-trifluoro-N- [6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide hemisuccinate 
• 613677-28-4 2,4,6-trifluoro-N-[6-(1-methylpiperidin-4-ylcarbonyl)-pyridin-2-yl]benzamide hydrochloride 

Relevant articles and documents

Preparation method of lasmiditan

The invention provides a preparation method of lasmiditan. Specifically, 2-bromo-6-aminopyridine is taken as a raw material and subjected to a condensation reaction with 2, 4, 6-trifluorobenzoyl chloride, and then the reaction product reacts with 1-methyl-4-ethyl piperidinecarboxylate to prepare the lasmiditan. The preparation method has the advantages of simple and safe synthesis route and operation, easily available raw materials, simple post-treatment and high yield, and is suitable for industrial production.

PROCESS FOR PREPARATION OF LASMIDITAN

The present invention relates to a process for the preparation of lasmiditan, a compound of formula I, or pharmaceutically acceptable salts thereof, the process comprising reacting a compound of formula IX with N-methoxymethylamine or salt thereof to obtain a compound of formula VII; reacting the compound of formula VII with a compound of formula XIV to obtain lasmiditan or salts thereof.

CRYSTALLINE FORM OF RECEPTOR AGONIST, AND MANUFACTURING METHOD AND PHARMACEUTICAL COMPOSITION THEREOF

The present invention relates to the crystalline forms of a 5-HT1F receptor agonist 2,4,6-trifluoro-N-[6-[(1-methyl-piperidine-4-yl)carbonyl]pyridin-2-yl]-benzene formamide (lasmiditan) and its hydrochloride. The crystalline forms of the presen